
WIPES

(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run: Wed Aug 16 09:46:34 2000; MasPar time 5.27 Seconds
Tabular output not generated. 453.799 Million cell updates/sec

Title: >US-09-427-873-2
Description: (1-101) from US09427873.pep
Perfect Score: 583
Sequence: 1 LGKFSQTCYNSAIQGSVLTS.....STKINLDDHIANIDGTLKYE 101

Scoring table: PAM 150
Gap 11

Searched: 188963 seqs, 23686106 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: a-geneseq36
1:genesep

Statistics: Mean 27.687; Variance 109.601; scale 0.253

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Rank	Score	Query %	Match	Length	ID	Description	Pred. No.
1	583	100.0	101	1	W80552	Antiviral protein, cya	8.24e-60
2	583	100.0	101	1	W67569	N. ellipsosporium cya	8.24e-60
3	583	100.0	101	1	W06811	Cyanovirin-N.	8.24e-60
4	583	100.0	109	1	W80553	Antiviral protein, cya	8.24e-60
5	583	100.0	109	1	W67570	FLAG epitope-cyanoviri	8.24e-60
6	583	100.0	109	1	W06812	FLAG-cyanovirin-N fusi	8.24e-60
7	88	12.9	618	1	W26541	Trypanosoma cruzi anti	9.36e+00
8	85	12.4	224	1	W76700	Mouse antioxidant prot	1.64e+01
9	85	12.4	224	1	W76699	Human antioxidant prot	1.64e+01
10	85	12.4	250	1	R34196	O-CSF.	1.64e+01
11	85	12.4	318	1	W09880	ACC oxidase GFE-1.	1.64e+01
12	82	12.0	258	1	W55071	Streptococcus pneumonia	2.86e+01
13	80	11.7	354	1	W30662	Human GDP-mannose 4,6-	4.12e+01
14	80	11.7	354	1	W39739	Human GM4, 6D protein #	4.12e+01
15	80	11.7	372	1	W30663	Human GDP-mannose 4,6-	4.12e+01
16	80	11.7	372	1	W39740	Human GM4, 6D protein #	4.12e+01
17	79	11.6	706	1	R68743	BCL-6 zinc finger prot	4.94e+01
18	78	11.4	84	1	W62708	Streptococcus pneumonia	5.92e+01
19	78	11.4	463	1	W19800	Glycyl-tRNA synthetase	5.92e+01
20	76	11.1	787	1	W53946	L.lactis MG1363 pfl pr	8.48e+01
21	76	11.1	1454	1	R42467	Feline infectious peri	8.48e+01
22	76	11.1	1454	1	R24397	Prod. of the S gene of	8.48e+01
23	76	11.1	1454	1	R42474	FEV/FIPV chimeric spi	8.48e+01

24	76	11.1	1454	1	R42470	Feline infectious peri	8.48e+01
25	76	11.1	1537	1	R11382	Partial human compleme	8.48e+01
26	76	11.1	1594	1	P81183	Sequence of the peplom	8.48e+01
27	76	11.1	1886	1	W54241	Rattus norvegicus muta	8.48e+01
28	76	11.1	1930	1	W45899	Human complement recep	8.48e+01
29	76	11.1	2039	1	R11810	Human complement type	8.48e+01
30	76	11.1	2039	1	R36743	CR1	8.48e+01
31	76	11.1	2317	1	P92219	CR1 protein	8.48e+01
32	75	11.0	1141	1	R66391	Human SREBP-2.	1.01e+02
33	74	10.8	369	1	W98475	H. pylori GHPO 885 pro	1.21e+02
34	74	10.8	787	1	W53941	L.lactis DB1341 pfl pr	1.21e+02
35	73	10.7	82	1	Y12911	Human 5' EST secreted	1.44e+02
36	73	10.7	514	1	R05535	Yeast aminopeptidase I	1.44e+02
37	72	10.5	138	1	R38152	Acetobacter CDG1d prot	1.72e+02
38	72	10.5	162	1	Y01079	Human bronchoalveolar	1.72e+02
39	72	10.5	207	1	W15288	Mouse oligodendrocyte	1.72e+02
40	72	10.5	425	1	W27163	Human TRAF inhibitor p	1.72e+02
41	72	10.5	1228	1	W22862	Bacillus stearothermop	1.72e+02
42	72	10.5	1228	1	R77673	S-layer protein encode	1.72e+02
43	71	10.4	2165	1	Y01819	L proteoin of Respirat	2.05e+02
44	71	10.4	2166	1	Y02005	L protein of RSV wild	2.05e+02
45	71	10.4	2166	1	Y02006	L protein of RSV wild	2.05e+02

ALIGNMENTS

RESULT 1
ID W80552 standard; Protein; 101 AA.
AC W80552;
DT 09-DEC-1998 (first entry)
DE Antiviral protein, cyanovirin-N.
KW Cyanovirin-N; recombinant; cyanovirin; cyanobacterium; antiviral;
KW HIV-1.
OS Nostoc ellipsosporium.
PN US5821081-A.
PD 13-OCT-1998.
PF 26-APR-1996; 638610.
PR 26-APR-1996; US-638610.
PR 27-APR-1995; US-429965.
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
PI Boyd MR/Gustafson KR, McMahon JB, Shoemaker RH;
DR WPI: 98-567657/48.
DR N-PSDB: V56025.
PT DNA encoding cyanovirin polypeptide(s) - useful for producing
PT recombinant polypeptides with antiviral activity
PS Claim 1; Fig 2; 33pp; English.
CC This represents an antiviral protein cyanovirin-N. A vector containing
CC a nucleic acid molecule (V56025 or V56026) can be used to transform a
CC host cell for the recombinant production of the cyanovirin polypeptides.
CC The cyanovirins are derived from the cyanobacterium Nostoc ellipsosporium,
CC and have antiviral activity, e.g. with EC50 values of 0.4-7.6 nM against
CC various HIV-1 strains and isolates.
SQ Sequence 101 AA;

Query Match 100.0%; Score 683; DB 1; Length 101;
Best Local Similarity 100.0%; Pred. No. 8.24e-60;
Matches 101; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db	1	LGKFSQTCYNSAIQGSVLTS	CERTNGYNTSSIDLSNVIENVDGSLKQWQSFNFIETCRN	60
QY	1	LGKFSQTCYNSAIQGSVLTS	CERTNGYNTSSIDLSNVIENVDGSLKQWQSFNFIETCRN	60

Db	61	TOLAGSSSLAAECKTRAQQFVSTKINLDDHIANIDGTLKYE	101
QY	61	TOLAGSSSLAAECKTRAQQFVSTKINLDDHIANIDGTLKYE	101

RESULT 2
ID W67569 standard; Protein; 101 AA.
AC W67569;
DT 02-MAR-1999 (first entry)
DE N. ellipsosporium cyanovirin protein.
KW Antiviral protein; cyanovirin; inhibition; infectivity; replication;

KW cytopathy; virus; HIV; infection.
 OS Nostoc ellipsoforum.
 PN US5843882-A.
 PD 01-DEC-1998.
 PF 27-APR-1995; 429965.
 PR 27-APR-1995; US-429965.
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PI Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH;
 DR WPI: 99-044625/04.
 N-PSDB: V34401.
 PT Nostoc ellipsoforum proteins or peptide(s) - with antiviral
 activity
 PS Claim 1: Column 25-26; 30pp; English.
 CC This sequence represents an antiviral protein, designated cyanovirin,
 from Nostoc ellipsoforum. The antiviral protein, or peptide of at least
 9 amino acid residues, is used to inhibit the infectivity, replication
 CC and cytopathic effects of viruses, especially HIV-1 or HIV-2, in the
 CC treatment or prevention of viral infections.
 SQ Sequence 101 AA;
 Query Match 100.0%; Score 683; DB 1; Length 101;
 Best Local Similarity 100.0%; Pred. No. 8.24e-60;
 Matches 101; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 LKFSQTCYNIAIQSVLTSTCERNGGYNTSSIDLNSVINDGSLKWQPSNFETCRN 60
 QY 1 LKFSQTCYNIAIQSVLTSTCERNGGYNTSSIDLNSVINDGSLKWQPSNFETCRN 60
 Db 61 TOLAGSSELAACKTRAAQFVSTKINLDDHIANIDGTLKYE 101
 QY 61 TOLAGSSELAACKTRAAQFVSTKINLDDHIANIDGTLKYE 101
 RESULT 3
 ID W06811 standard; Protein; 101 AA.
 AC W06811.
 DT 17-MAR-1997 (first entry)
 DE Cyanovirin-N.
 KW Cyanovirin-N; cyanobacterium; antiviral; virucide; HIV-1; HIV-2;
 KW SIV; human immunodeficiency virus; retrovirus; AIDS; therapy.
 OS Nostoc ellipsoforum.
 PN W0681107-A2.
 PD 31-OCT-1996.
 PF 26-APR-1996; U05908.
 PR 27-APR-1995; US-429965.
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PI Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH;
 DR WPI: 96-497638/49.
 N-PSDB: T45976.
 PT Antiviral protein from Nostoc ellipsoforum - used for treating or
 preventing viral infections, esp. infections caused by retroviruses
 such as HIV
 PS Claim 2: Page 78; 99pp; English.
 CC Cyanovirin-N (W06811) of Nostoc ellipsoforum shows antiviral
 CC activity against immunodeficiency retroviruses, esp. HIV-1, HIV-2
 CC and SIV. It was detected in aq. extracts of the cyanobacterium
 CC using an HIV-specific bioassay-guided strategy. It can be obtained by
 CC expression in host (esp. yeast, lactobacilli) cells transformed
 CC with a vector carrying cyanovirin-N sequences (see also T45978-79).
 CC It can also be produced as a conjugate with e.g. a toxin (esp.
 CC Pseudomonas exotoxin) or immunological agent. It is used to treat
 CC or prevent viral infections, and to prevent the spread of such
 CC infections by treating inanimate objects, ex vivo blood, blood
 CC prods. or tissue.
 SQ Sequence 101 AA;
 Query Match 100.0%; Score 683; DB 1; Length 101;
 Best Local Similarity 100.0%; Pred. No. 8.24e-60;
 Matches 101; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 LKFSQTCYNIAIQSVLTSTCERNGGYNTSSIDLNSVINDGSLKWQPSNFETCRN 60
 QY 1 LKFSQTCYNIAIQSVLTSTCERNGGYNTSSIDLNSVINDGSLKWQPSNFETCRN 60

Db 61 TOLAGSSELAACKTRAAQFVSTKINLDDHIANIDGTLKYE 101
 QY 61 TOLAGSSELAACKTRAAQFVSTKINLDDHIANIDGTLKYE 101
 RESULT 4
 ID W80553 standard; Protein; 109 AA.
 AC W80553.
 DT 09-DEC-1998 (first entry)
 DE Antiviral protein, cyanovirin-N.
 KW Cyanovirin-N; recombinant; cyanovirin; cyanobacterium; antiviral;
 KW HIV-1.
 OS Nostoc ellipsoforum.
 FH Key Location/Qualifiers
 FT Peptide 1..8
 FT /note= "FLAG octapeptide"
 PN US5821081-A.
 PD 13-OCT-1998.
 PF 26-APR-1996; 638610.
 PR 26-APR-1996; US-638610.
 PR 27-APR-1995; US-429965.
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PI Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH;
 DR WPI: 98-567657/48.
 N-PSDB: V56026.
 PT DNA encoding cyanovirin polypeptide(s) - useful for producing
 PT recombinant polypeptides with antiviral activity
 PS Claim 1; Fig 2; 33pp; English.
 CC This represents an antiviral protein cyanovirin-N. A vector containing
 CC a nucleic acid molecule (V56025 or V56026) can be used to transform a
 CC host cell for the recombinant production of the cyanovirin polypeptides.
 CC The cyanovirins are derived from the cyanobacterium Nostoc ellipsoforum,
 CC and have antiviral activity, e.g. with EC50 values of 0.4-7.6 nM against
 CC various HIV-1 strains and isolates.
 SQ Sequence 109 AA;
 Query Match 100.0%; Score 683; DB 1; Length 109;
 Best Local Similarity 100.0%; Pred. No. 8.24e-60;
 Matches 101; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 9 LKFSQTCYNIAIQSVLTSTCERNGGYNTSSIDLNSVINDGSLKWQPSNFETCRN 68
 QY 1 LKFSQTCYNIAIQSVLTSTCERNGGYNTSSIDLNSVINDGSLKWQPSNFETCRN 60
 Db 69 TOLAGSSELAACKTRAAQFVSTKINLDDHIANIDGTLKYE 109
 QY 61 TOLAGSSELAACKTRAAQFVSTKINLDDHIANIDGTLKYE 101
 RESULT 5
 ID W67570 standard; Protein; 109 AA.
 AC W67570.
 DT 02-MAR-1999 (first entry)
 DE FLAG epitope-cyanovirin fusion protein.
 KW Antiviral protein; cyanovirin; inhibition; infectivity; replication;
 KW cytopathy; virus; HIV; infection; epitope.
 OS Synthetic.
 OS Nostoc ellipsoforum.
 FH Key Location/Qualifiers
 FT Region 1..8
 FT /label= FLAG-epitope
 FT Region 10..109
 FT /label= cyanovirin_N
 PN US5843882-A.
 PD 01-DEC-1998.
 PF 27-APR-1995; 429965.
 PR 27-APR-1995; US-429965.
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PI Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH;
 DR WPI: 99-044625/04.
 N-PSDB: V34402.
 PT Nostoc ellipsoforum proteins or peptide(s) - with antiviral

PT activity
 PS Disclosure: Column 27-28; 30pp; English.
 CC This sequence represents a synthetic fusion protein comprising the
 CC antiviral protein, designated cyanovirin, from Nostoc ellipsosporum
 CC with a FLAG epitope peptide fused at its N-terminus. The antiviral
 CC protein, or peptide of at least 9 amino acid residues, is used to
 CC inhibit the infectivity, replication and cytopathic effects of viruses,
 CC especially HIV-1 or HIV-2, in the treatment or prevention of viral
 CC infections.
 SQ Sequence 109 AA;

Query Match 100.0%; Score 683; DB 1; Length 109;
 Best Local Similarity 100.0%; Pred. No. 8.24e-60;
 Matches 101; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 9 LGRFSQTCYNSAIOGSLTTCERTNGGYNTSSIDLNSVIENVDSGLKWQPSNFIETCRN 68
 QY 1 LGRFSQTCYNSAIOGSLTTCERTNGGYNTSSIDLNSVIENVDSGLKWQPSNFIETCRN 60
 D 69 TQLAGSSELAEECKTRAQQFVSTKINLDDHIANIDGTLKYE 109
 QY 61 TQLAGSSELAEECKTRAQQFVSTKINLDDHIANIDGTLKYE 101

RESULT 6
 ID W06812 standard; Protein; 109 AA.
 AC W06812;
 DT 17-MAR-1997 (first entry)
 DE FLAG-cyanovirin-N fusion protein.
 KW Cyanovirin-N: cyanobacterium; antiviral; virucide; HIV-1; HIV-2;
 KW SIV; human immunodeficiency virus; retrovirus; AIDS; therapy.
 OS Chimeric Nostoc ellipsosporum;
 OS Chimeric synthetic.
 FH Key Location/Qualifiers
 FT peptide 1..8
 FT /label= FLAG
 FT protein 9..109
 FT /label= Cyanovirin-N
 FT W09634107-A2.
 PD 31-OCT-1996.
 PF 26-APR-1996; U05908.
 PR 27-APR-1995; US-429965.
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PI Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH;
 DR WPI; 96-497638/49.
 DR N-PSDB; T45979.
 PT Antiviral protein from Nostoc ellipsosporum - used for treating or
 PT preventing viral infections, esp. infections caused by retroviruses
 PT such as HIV
 PS Example 2; Page 79-80; 99pp; English.
 CC A polypeptide (W06812) comprises a FLAG octapeptide fused to the
 CC antiviral cyanovirin-N (see also W06811) of Nostoc ellipsosporum.
 CC It can be produced in transformed host cells utilising the pFLAG-1
 CC vector including a synthetic gene (T45979) and purified using
 CC anti-FLAG antibodies. Cyanovirin-N shows antiviral activity
 CC against immunodeficiency retroviruses, esp. HIV-1, HIV-2 and SIV.
 CC It can also be produced as a conjugate with e.g. a toxin (esp.
 CC pseudomonas exotoxin) or immunological agent. It is used to treat
 CC or prevent viral infections, and to prevent the spread of such
 CC infections by treating inanimate objects, ex vivo blood, blood
 CC prods. or tissue.
 SQ Sequence 109 AA;

Query Match 100.0%; Score 683; DB 1; Length 109;
 Best Local Similarity 100.0%; Pred. No. 8.24e-60;
 Matches 101; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 9 LGRFSQTCYNSAIOGSLTTCERTNGGYNTSSIDLNSVIENVDSGLKWQPSNFIETCRN 68
 QY 1 LGRFSQTCYNSAIOGSLTTCERTNGGYNTSSIDLNSVIENVDSGLKWQPSNFIETCRN 60
 D 69 TQLAGSSELAEECKTRAQQFVSTKINLDDHIANIDGTLKYE 109
 QY 61 TQLAGSSELAEECKTRAQQFVSTKINLDDHIANIDGTLKYE 101

QY 61 TQLAGSSELAEECKTRAQQFVSTKINLDDHIANIDGTLKYE 101

RESULT 7
 ID W26541 standard; Protein; 618 AA.
 AC W26541;
 DT 12-JAN-1998 (first entry)
 DE Trypanosoma cruzi antigen.
 KW Antigen; epitope; vaccine; protective immunity; Chagas disease;
 KW diagnosis; therapy; immunoassay.
 OS Trypanosoma cruzi Tulahean strain C2.
 PN W09718475-A1.
 PD 22-MAY-1997.
 PF 14-NOV-1996; U18624.
 PR 14-NOV-1995; US-557309.
 PA (CORI-) CORIXA CORP.
 PI Houghton RL, Lodes MJ, Reed SG, Skeiky YAW;
 DR WPI; 97-289413/26.
 DR N-PSDB; T69167.
 PT Diagnosing Trypanosoma cruzi infection by detecting antibodies to
 PT novel antigens - which are useful in vaccines to provide protective
 PT immunity against Chagas' disease
 PS Disclosure; Page 88-91; 110pp; English.
 CC This polypeptide sequence comprises a full-length antigen of
 CC Trypanosoma cruzi, identified by sequencing a DNA clone (see T69167)
 CC obtained by screening a Trypanosoma cruzi genomic expression library
 CC with pools of sera from infected individuals. T. cruzi antigens
 CC (see W26530-41), or epitope-containing repeat sequences (see W19094-
 CC 102, W19079-86 and W26542-44) of native antigens, can be used in a
 CC variety of immunoassays for detecting T. cruzi infection in a
 CC blood, serum, plasma, saliva, cerebrospinal fluid or urine sample.
 CC The polypeptides are also useful in vaccines and pharmaceutical
 CC compositions for inducing protective immunity against Chagas
 CC disease. They can be produced by expression in transformed or
 CC transfected host cells.
 SQ Sequence 618 AA;

Query Match 12.9%; Score 88; DB 1; Length 618;
 Best Local Similarity 30.0%; Pred. No. 9.36e+00;
 Matches 15; Conservative 14; Mismatches 18; Indels 3; Gaps 3;

DB 350 GGNLISLYENKSGSLVAVHTTOLERIKTVLKRWQELDEALTRCRST 399
 QY 15 GSVLTSTCE-RTNGGYNTSSIDLNSVIENVDSGLK-WQP-SNFIETCRNT 61

RESULT 8
 ID W76700 standard; Protein; 224 AA.
 AC W76700;
 DT 02-FEB-1999 (first entry)
 DE Mouse antioxidant protein 2 (AOP2).
 KW Antioxidant protein 2; AOP2; mouse; atherosclerosis; Ath1;
 KW heart disease; diagnosis; therapy; drug screening.
 OS Mus sp.
 FH Key Location/Qualifiers
 FT Misc_difference 124
 FT /note= "Asp in DBA/2J, C3H and BALB/c mice, and
 FT Ala in C57BL/6J"
 PN W09843666-A1.
 PD 08-OCT-1998.
 PF 01-APR-1998; U066666.
 PR 02-APR-1997; US-040897.
 PA (BGHM) BRIGHAM & WOMENS HOSPITAL.
 PI (JACK-) JACKSON LAB.
 PI Beier DR, Paigen B;
 DR WPI; 98-56267/48.
 DR N-PSDB; V62048.
 PT New isolated antioxidant protein 2 gene - used to develop products
 PT for modulating antioxidant activity in vivo and for treatment of
 PT oxidative damage, atherosclerosis and heart disease
 PS Claim 5; Page 115; 139pp; English.
 CC This is the amino acid sequence of novel murine antioxidant protein
 CC 2 (AOP2), as deduced from an Aop2 cDNA sequence (see V62048). The

SQ sequence 224 AA;

PS Disclosure:

RESULT 13
ID W30662 standard; Protein; 354 AA.
AC W30662;

Query Match	11.7%;	Score 80;	DB 1;	Length 354;
Best Local Similarity	21.1%;	Pred. No. 4.12e+01;		

	Matches	16;	Conservative	26;	Mismatches	30;	Indels	4;	Gaps	4;
Db	37	RRSSFNTRGIEHLYNPNQAHISGNKMLHYGDUTDSTCL-VKTIINEVKTEYNLGAQSH	95							
QY	24	RTNGYNTSSID-L-NSVINDVDSGLKWPFSNFIE-TCRNTQLAGSSELAABECKTRAQOF	80							
Db	96	VKISFDLAEYTDVVG	111							
QY	81	VSTKINLDDHIANIDG	96							

RESULT	15	
AD	W30663 standard; Protein; 372 AA.	
ID	W30663;	
DE	13-APR-1999 (first entry)	
DT	Human GDP-mannose 4,6-dehydratase protein #2.	
DE	Human GDP-mannose 4,6-dehydratase; GM4,6D; fucosylation;	
KW	Human; GDP-mannose 4,6-dehydratase; GM4,6D; fucosylation;	
KW	glycoconjugate.	
KW		
OS	Homo sapiens.	
PN	95869307-A.	
PD	95-FEB-1999.	
PF	03-DEC-1997; 984246.	
PR	22-NOV-1996; US-753233.	
PR	03-DEC-1997; US-984246.	
PA	(GEM) GENETICS INST INC.	
PI	Kriz R, Kumar R, Sullivan F;	
DR	WPI; 99-152775/13.	
DR	N-PSDB; X03922.	
PT	Human GDP-mannose 4,6-dehydratase polypeptide - useful in drug	
PT	screening assays	
PS	Claim 1; Column 11-14; 9pp; English.	
CC	The present invention describes a nucleotide sequence encoding two human	
CC	GDP-mannose 4,6-dehydratase (GM4,6D) proteins comprising 354 or 372	
CC	amino acids. The shorter protein represents amino acid residues 19 to	
CC	372 of the longer protein, and they both have GM4,6D activity. The	
CC	present sequence represents the longer GM4,6D protein. The GM4,6D	
CC	enzyme is useful for screening for GM4,6D inhibitors in assays, which	
CC	would be useful for treating diseases affected by the level of cellular	
CC	fucosylation or the fucosylation of glycoconjugates.	
CC	Sequence 372 AA;	
SQ		

Search completed: Wed Aug 16 09:46:42 2000
Job time : 8 secs.